Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Emcure Pharmaceuticals Limited

EMCURE · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,871.80

+₹6.80 (+0.36%)(1D)

₹1,306.5052 Week Range₹2,100.70

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

59/100

Valuation

40/100

Quality

87/100

Growth

11/100

Health

87/100

Momentum

72/100

Valuation
40
Quality
87
Growth
11
Health
87
Momentum
72

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Emcure Pharmaceuticals Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,871.8

Market cap

₹35,492 Cr

P/E ratio

35.09

P/B ratio

7.17

Dividend yield

Not available

ROE

Not available

RSI 14

51.54

1Y return

Not available

Emcure Pharmaceuticals Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Emcure Pharmaceuticals Limited (EMCURE) stock page cover?

Emcure Pharmaceuticals Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for EMCURE?

Emcure Pharmaceuticals Limited is currently shown with a delayed price near ₹1,871.8, P/E 35.09.

Does the EMCURE page provide investment advice?

No. The EMCURE page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

WOCKPHARMA

Wockhardt Limited · Healthcare

PPLPHARMA

Piramal Pharma Limited · Healthcare

AJANTPHARM

Ajanta Pharma Limited · Healthcare

Automated Forensic Screening: Detecting Cash Flow & Promoter Pledge Red Flags

Screen for corporate governance risks, CFO vs EBITDA divergence, and promoter pledge spikes in Indian stocks using Anvest.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Emcure Pharmaceuticals Limited operates in the pharmaceutical sector, focusing on complex products like injectables and biosimilars. The company generates revenue from domestic sales and international markets, including Europe and Canada.

Drug Manufacturers - Specialty & GenericFounded:1981CEO/MD:Satish MehtaHQ:Pune, Maharashtra

Business at a Glance

It has a strong presence in the domestic market and exports to Europe, Canada, and other Rest of World (RoW) regions.

What Looks Strong

Financial highlights are being recalculated.

What to Watch

Financial highlights are being recalculated.

Reports a single operating segment in its results filings.
Emcure Pharmaceuticals generates revenue by developing, manufacturing, and selling both specialty and generic pharmaceutical products.
This includes active pharmaceutical ingredients (APIs) and finished dosage forms, catering to domestic and international markets through a robust sales and distribution network.